Humacyte First Quarter 2022 Financial Results and Business Update
-- Human Acellular Vessels™ (HAVs™) shipped to six hospitals in Ukraine for treatment of civilian and military vascular trauma injuries --
-- Strengthened leadership team with appointment of Shamik Parikh M.D., as Chief Medical Officer --
-- Multiple scientific meeting presentations and publications highlighting clinical and preclinical HAV data --
-- Conference call and live webcast at 8:00 a.m. ET today --
DURHAM, N.C., May 13, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues, complex tissue systems, and organs at commercial scale, today announced financial results for the first quarter ended March 31, 2022, and highlighted recent corporate accomplishments.
“We are pleased by the progress Humacyte has made in the first quarter of 2022 as we continue to advance our universally implantable, bioengineered human tissue platform. We believe our lead candidate, the HAV, is uniquely suited for scenarios in which the current standard of care is unavailable or inadequate. During the humanitarian crisis in Ukraine, we are proud to be able to provide HAVs to front-line hospitals for the treatment of military and civilian vascular trauma injuries.” said Laura Niklason, M.D., Ph.D., Founder, President and Chief Executive Officer of Humacyte. “In addition, we were pleased to welcome Dr. Shamik Parikh as our Chief Medical Officer. Dr. Parikh joins us at a pivotal time, as we look forward to the planned completion of our late-stage clinical trials in vascular trauma and arteriovenous access for hemodialysis and, if approved, work to bring the HAV to market in its initial indications.”
First Quarter 2022 and Recent Corporate Highlights
First Quarter 2022 Financial Highlights
Conference Call and Webcast Details
A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the investors section of the Company’s website for at least 30 days.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands except for share and per share amounts)
Condensed Consolidated Balance Sheets